Today, we’re going on a journey to explore the estimated Dr Reddy Share Price Target for the years 2023 to 2050. We will use our Research and the company’s growth prospects to make a prediction. By the end of our journey, you will have a better understanding of the expected Dr Reddy Share Price Target.
As an investor or a beginner interested in Dr Reddy, it is essential to understand the potential of Dr Reddy’s share price prediction. We will analyze the performance of the company’s shares in recent times and provide you with a well-researched Dr Reddy Share price target for 2023, 2025, 2030 to 2050.
Additionally, we will also take into account analyst recommendations from various brokerage firms, including target high price, target low price, mean recommendation, and key recommendation.
Overview of Dr Reddy
| Name | Dr Reddy’s Laboratories |
| Industry | Pharmaceuticals |
| Type | Public |
| Founded | 1984 |
| CEO | Gautam Reddy |
| Headquarters | Hyderabad, India |
| Services | Drug discovery development manufacturing |
| Country | India |
| Locations | Over 60 countries |
| Website | drreddys.com |
| Profile | Dr._Reddy |
Keep an eye on Dr Reddy’s share price today with real-time updates, and examine its performance on the stock market through comprehensive charts that display the fluctuations in Dr Reddy’s share price.
Fundamentals of Dr Reddy
The fundamental analysis of Dr Reddy Limited focuses on key factors to better understand the company’s valuation. Various valuation techniques have been used, including the Price-to-Earnings Ratio (P/E), Price-to-Sales Ratio (P/S), Price-to-Book Value Ratio (P/B), Dividend Yield, and other Details.
Dr. Reddy’s Laboratories Ltd. is a multinational pharmaceutical company based in India. The company was founded in 1984 and has since grown to become one of the largest pharmaceutical companies in India.
Dr. Reddy’s Laboratories Ltd. specializes in the development, manufacture, and marketing of a wide range of pharmaceutical products, including generic drugs, active pharmaceutical ingredients (APIs), and proprietary products.
The company operates in over 20 countries worldwide and has a strong presence in the United States, India, and Europe. Dr. Reddy’s Laboratories Ltd. is committed to providing affordable and innovative healthcare solutions to patients around the world.
- Promoters: 26.70%
- Mutual Funds: 9.87%
- Foreign Institutions: 27.25%
- Retail And Others: 23.17%
- Other Domestic Institutions: 13.01%
| Competitor | Market Share |
|---|---|
| Sun Pharma | 14.4% |
| Lupin | 13.2% |
| Aurobindo Pharma | 11.7% |
| Cipla | 10.4% |
| Glenmark Pharmaceuticals | 7.6% |
| Cadila Healthcare | 6.7% |
| Torrent Pharmaceuticals | 5.8% |
| Dr. Reddy’s Laboratories | 5.4% |
Brokerage Firms
An effective method for evaluating the Dr Reddy share price Target is by examining research reports and analyses conducted by reputable financial institutions and brokerage firms.
| DATE | AUTHOR | TARGET | TYPE |
|---|---|---|---|
| 04 JUL 2023 | Sharekhan | 5963.00 |
Buy
|
| 23 JUN 2023 | Motilal Oswal | 4680.00 |
Neutral
|
| 12 MAY 2023 | KRChoksey | 5155.00 |
Buy
|
| 11 MAY 2023 | BOB Capital Markets Ltd. | 4900.00 |
Hold
|
| 11 MAY 2023 | ICICI Direct | 5520.00 |
Buy
|
| 11 MAY 2023 | Motilal Oswal | 4500.00 |
Neutral
|
| 11 MAY 2023 | Axis Direct | 5100.00 |
Hold
|
| 11 MAY 2023 | Prabhudas Lilladhar | 4500.00 |
Sell
|
| 07 FEB 2023 | Geojit BNP Paribas | 5166.00 |
Buy
|
| 27 JAN 2023 | ICICI Direct | 5210.00 |
Buy
|
| 27 JAN 2023 | Axis Direct | 5100.00 |
Buy
|
| 27 JAN 2023 | ICICI Securities Limited | 5131.00 |
Buy
|
| 26 JAN 2023 | BOB Capital Markets Ltd. | 4700.00 |
Hold
|
Our Recommendation
| Telegram Channel | 👉 Click Here ☑ |
| Facebook Page | 👉 Click Here ☑ |
We will analyze the performance of the company’s shares in recent times and provide you with a well-researched Dr Reddy price target for 2023, 2025 to 2030, based on our Research knowledge and forecasting.
Our minimum prediction for Dr Reddy share price target in 2023 is ₹5700. We believe that the company’s strong product pipeline and business conditions will continue to drive growth in the coming years. Dr. Reddy’s Laboratories Ltd. has a healthy balance sheet and a strong ROE of 17.5%, which is a testament to the company’s financial stability.
Additionally, the company recently announced its foray into the trade generics business in India, which is expected to drive volume growth and overall revenue growth marginally higher over FY2023-FY2025E. These factors, combined with the company’s attractive valuation of ~18.1x/~17.1x its revised FY2024E/FY2025E EPS estimates, make us confident in our minimum target of ₹5700.
Our maximum prediction for Dr Reddy share price target in 2023 is ₹6200. We believe that the company’s strong product pipeline and business conditions will continue to drive growth in the coming years. Dr. Reddy’s Laboratories Ltd. has a strong presence in the United States, India, and Europe, which gives the company a wide reach and a diverse customer base.
Additionally, the company’s commitment to providing affordable and innovative healthcare solutions to patients around the world is a testament to its long-term growth potential. These factors, combined with the company’s attractive valuation of ~18.1x/~17.1x its revised FY2024E/FY2025E EPS estimates, make us confident in our maximum target of ₹6200.
For 2024, we estimate a minimum target of ₹6200 and a maximum target of ₹6700. We believe that the company’s strong product pipeline and business conditions will continue to drive growth in the coming years, and that the company’s commitment to providing affordable and innovative healthcare solutions to patients around the world will be a key driver of its long-term success. Additionally, the company’s recent foray into the trade generics business in India is expected to drive volume growth and overall revenue growth marginally higher over FY2023-FY2025E.
Looking ahead to 2025, we estimate a minimum target of ₹7000 and a maximum target of ₹7500. We believe that the company’s strong product pipeline and business conditions will continue to drive growth in the coming years, and that the company’s commitment to providing affordable and innovative healthcare solutions to patients around the world will be a key driver of its long-term success.
Additionally, the company’s recent for ay into the trade generics business in India is expected to drive volume growth and overall revenue growth marginally higher over FY2023-FY2025E. Furthermore, the company’s focus on complex generics and first-to-market products is expected to drive profitable growth in North America over the short to long term.
Looking ahead to 2027, we estimate a minimum target of ₹9000 and a maximum target of ₹9500. We believe that the company’s strong product pipeline and business conditions will continue to drive growth in the coming years, and that the company’s commitment to providing affordable and innovative healthcare solutions to patients around the world will be a key driver of its long-term success. Additionally, the company’s focus on complex generics and first-to-market products is expected to drive profitable growth in North America over the short to long term.
Looking further ahead, we estimate a minimum target of ₹8000 and a maximum target of ₹10,000 for 2030. By this time, we believe that the company’s strong product pipeline and business conditions will continue to drive growth, and that the company’s commitment to providing affordable and innovative healthcare solutions to patients around the world will be a key driver of its long-term success. Additionally, the company’s focus on complex generics and first-to-market products is expected to drive profitable growth in North America over the short to long term.
Looking even further ahead, we estimate a minimum target of ₹15,000 and a maximum target of ₹20,000 for 2040, and a minimum target of ₹25,000 and a maximum target of ₹30,000 for 2050.
These targets are based on our analysis of the company’s financial performance and growth prospects and are subject to change based on a wide range of variables and uncertainties. However, we believe that Dr. Reddy’s Laboratories Ltd. has a strong foundation and a clear strategy for growth, which should enable it to continue delivering value to its shareholders over the long term.
| Years | Minimum Target | Maximum Target |
|---|---|---|
| 2023 | ₹5700 | ₹6200 |
| 2024 | ₹6200 | ₹6700 |
| 2025 | ₹7000 | ₹7500 |
| 2026 | ₹8000 | ₹8500 |
| 2027 | ₹9000 | ₹9500 |
| 2030 | ₹8000 | ₹10,000 |
| 2040 | ₹15,000 | ₹20,000 |
| 2050 | ₹25,000 | ₹30,000 |
Based on our analysis, the maximum share price target for Dr Reddy in 2023 could be ₹6200.
Based on our analysis, the maximum share price target for Dr Reddy in 2025 could be ₹7500.
Based on our analysis, the maximum share price target for Dr Reddy in 2030 could be ₹10,000.
To stay updated with the latest information related to the stock market and receive live stock market updates, follow Sharedhan and stay connected with us.
I would like to remind you that I am not authorized by SEBI to provide any financial advice or recommendations. As you know, Share price prediction is not an exact science, That’s why I am conducting in-depth research and using different AI tools to predict share prices. My purpose is only educational, and I am using AI to see what the future of the stock might look like.
Disclaimer– That these Share Price Targets for “Dr Reddy Share Price Target” is only provided for informational purposes only. It does not constitute a recommendation to buy, sell or hold Dr Reddy stock. Investors should conduct their own research and analysis and consult with financial experts before making any investment decisions— Sharedhan.com
